OGB21502 / Onegene - LARVOL DELTA

Unlocking Powerful Biology: OGB21502 is a Tetra- Specific Drug (GLP-1 X GCG X FGF21 X IL1RA) to Treat NASH & Liver Fibrosis (NASH Summit-US 2023) - "Synopsis Novel protein-protein conjugation technology, which enables the facile development of multi-modalities, multi-targeting drugs Can IL-1 blocking make synergy in improving fibrosis and metabolism? Preclinical findings recommend transitioning towards the clinical stage in 2024"

Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Non-alcoholic Steatohepatitis • FGF21 • GCG • IL1R1

THERAPEUTIC EFFECTS OF OGB21502, A NOVEL TETRA-SPECIFIC DRUG, IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) MICE MODELS (AASLD 2023) - "In the remaining 8 weeks, the mice were administered either OGB21502 or reference drugs (Fc-FGF21, obeticholic acid and semaglutide). Overall, a novel tetra-specific drug, OGB21502 improved glucose level, insulin resistance, liver damage, inflammation as well as liver fibrosis through multiple animal models. These results demonstrate the potential of OGB21502 as an important alternative for treating severe NASH with metabolic dysfunction and fibrosis, due to synergistic effects across multiple targets."

Preclinical • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Non-alcoholic Steatohepatitis • Obesity • Type 2 Diabetes Mellitus • FGF21 • GCG • IL1R1 • TGFB1

Effects of a novel tetra-specific drug (OGB21502) in the obese mice model of liver disease (EASL-ILC 2023) - "In the remaining 8 weeks, the mice were administered either OGB21502 or reference drugs (Fc-FGF21, obeticholic acid and semaglutide). OGB21502 treatment improved glucose level, insulin resistance, liver damage, as well as cholesterol accumulation in the GAN-DIO mice. OGB21502 treatment might also be effective in controlling glucose metabolism by targeting liver, compared to reference therapeutics. The results suggest that OGB21502 may be a promising multi-specific therapeutic option for the treatment of NASH."

Preclinical • Diabetes • Genetic Disorders • Hepatology • Inflammation • Liver Failure • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity • Type 2 Diabetes Mellitus • FGF21 • GCG

Anti-fibrotic potential of a novel long-acting GLP-1/GCG/FGF21/IL-1RA tetra-specific drug (OGB21502) in preclinical mice models (EASD 2022) - "Liraglutide and dulaglutide were used as comparative controls...The OGB21502 or comparative control such as Fc-FGF21(RGE) and Ocaliva (OCA) was subcutaneously administered for the last 4 weeks... Overall, the composite mechanism of action of OGB21502 significant improved inflammation as well as fibrosis through multiple animal models. It is also expected to be effective in fibrosis in other organs. Therefore, these findings prompt the evaluation of a novel multi-specific therapeutic potential of OGB21502 for NASH with liver fibrosis and other fibrotic diseases."

Preclinical • Non-alcoholic Steatohepatitis • COL1A1 • FGF21 • IL1R1 • TGFB1

[VIRTUAL] Therapeutic effect of a novel long-acting GLP-1/GCG/FGF21/anti-cytokine tetra-specific drug (OGB21502) in MCD diet-fed NASH mice model (EASD 2021) - "Liraglutide (Saxenda, Eli lilly) and dulaglutide (Trulicity, Eli lilly) was used as comparative control. Based on these results, OGB21502 offer therapeutic anti-inflammatory and NASH improvement benefits. Multi-target approach created by UniStac technology offer a therapeutic potential for NASH and fibrosis."

Preclinical • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • FGF21 • FGFR1 • TGFB1

[VIRTUAL] Anti-fibrotic effect of a novel long-acting GLP-1/GCG/FGF21/anti-cytokine tetra-specific drug (OGB21502) in CCl4-induced liver fibrosis mice (EASD 2021) - "Ocaliva was used as comparative control. Based on these results, OGB21502 offer therapeutic anti-inflammatory and anti-fibrotic effects. OGB21502, based on UniStac technology, induce synergies of multiple targets, improving NASH and fibrosis."

Preclinical • Metabolic Disorders • Non-alcoholic Steatohepatitis • CCL4 • FGF21 • FGFR1 • TGFB1